BCMA-Targeted Antibodies & T-Cells in: October 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells
BCMA-Targeted Antibodies & T-Cells in:
October 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells
This pdf report contains information about TCR & CAR engineered T-cells and NK cells released during the month of October 2016. This issue forms part of the subscription service R&D and Business Tracker for TCR & CAR T-Cells and NK Cells
Featured presentations of October 2016 include the pipeline of B-Cell Maturation Antigen (BCMA)-targeted antibodies & T-cells, the profile of US biotech Poseida Therapeutics and the profile of anti-BCMA CARtyrin T-cell product candidate P-BCMA-101 from Poseida Therapeutics.
The October 2016 issue of La Merie Publishing‘s R&D and Business Tracker service about TCR & CAR engineered T-cells and NK cells contains:
R&D and Technology Tracker
Scientific Publication Tracker
Featured Cell Therapy Profile: P-BCMA-101 Featured Company Profile: Poseida Therapuetics
Featured Target or Technology Pipeline: BCMA-Targeted Antibodies & T-Cellls
BCMA-Targeted Antibodies & T-Cells include:
Methodology:
Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing’s proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.
Customized Update Service:
The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.
October 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells
This pdf report contains information about TCR & CAR engineered T-cells and NK cells released during the month of October 2016. This issue forms part of the subscription service R&D and Business Tracker for TCR & CAR T-Cells and NK Cells
Featured presentations of October 2016 include the pipeline of B-Cell Maturation Antigen (BCMA)-targeted antibodies & T-cells, the profile of US biotech Poseida Therapeutics and the profile of anti-BCMA CARtyrin T-cell product candidate P-BCMA-101 from Poseida Therapeutics.
The October 2016 issue of La Merie Publishing‘s R&D and Business Tracker service about TCR & CAR engineered T-cells and NK cells contains:
R&D and Technology Tracker
- Pipeline changes
- Regulatory news
- Technology validations
- Company updates
- Collaboration
- Licensing
- Merger & acquisitions
- Financing
Scientific Publication Tracker
Featured Cell Therapy Profile: P-BCMA-101 Featured Company Profile: Poseida Therapuetics
Featured Target or Technology Pipeline: BCMA-Targeted Antibodies & T-Cellls
BCMA-Targeted Antibodies & T-Cells include:
- Autologous & allogeneic T-Cells
- Bispecific tumor-targeted antibodies & T-cells
- Bispecific T-Cell and NK-Cell redirecting antibodies
- Antibody-Drug Conjugates
Methodology:
Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing’s proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.
Customized Update Service:
The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.
More Publications
TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs
US$ 2,626.00
August 2016
388 pages
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H2 2018
US$ 3,500.00
November 2018
64 pages
Competitor Analysis: Amyloid beta- and Tau-Targeted Antibodies & Vaccines
US$ 345.00
September 2015
44 pages
BCMA-Targeted Immunotherapeutics in: October 2016 R&D and Business Tracker for Bispecific Antibodies
US$ 225.00
November 2016
21 pages
CD33-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells
US$ 225.00
October 2016
25 pages
